# Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

> **NCT03512210** · PHASE4 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 400 (actual)

## Conditions studied

- Hepatitis C
- HIV-1-infection
- Liver Diseases

## Interventions

- **DRUG:** Sofosbuvir/Velpatasvir (SOF/VEL)
- **OTHER:** Minimal Monitoring (MINMON) Strategy

## Key facts

- **NCT ID:** NCT03512210
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-22
- **Primary completion:** 2020-07-30
- **Final completion:** 2021-02-28
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2022-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03512210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03512210, "Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03512210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*